# Hims & Hers Health

Type: Company (HIMS)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/hims-hers-health
Canonical HTML page: https://gethealthbrief.com/entity/hims-hers-health

## Recent coverage (4 stories)

### Hims Q2 revenue hits $753M; Alcon eye care grows 7%
2026-08-18 00:45:06 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Hims & Hers posted 38% revenue growth and 2.89M subscribers while absorbing $81M in nonrecurring charges, and Alcon's core EPS rose 9% to $0.84. Telehealth demand and ocular health innovation are driving divergent profit outcomes.
Full story: https://gethealthbrief.com/story/health-hims-alcon-q2-2026-earnings

### Hims & Hers Surges 41% on Landmark GLP-1 Distribution Deal with Novo Nordisk
2026-03-10 00:20:04 · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hims & Hers Health has secured a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The deal marks a pivotal shift for the telehealth provider from compounded alternatives to FDA-approved Ozempic, triggering a massive 41% rally in its share price.
Full story: https://gethealthbrief.com/story/hims-and-hers-novo-nordisk-glp1-partnership

### Hims & Hers to Halt Compounded GLP-1 Sales Following Legal Settlement
2026-03-09 17:34:05 · Sentiment: Negative · Impact: 6/10 · Sources: 2

Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in its weight-loss business strategy. This move follows mounting pressure from pharmaceutical manufacturers and highlights the tightening regulatory environment for telehealth platforms leveraging drug shortages.
Full story: https://gethealthbrief.com/story/hims-hers-settles-glp1-lawsuit-compounding

### Hims & Hers and Novo Nordisk Settle GLP-1 Dispute, Pivot to Partnership
2026-03-09 17:32:30 · Sentiment: Positive · Impact: 6/10 · Sources: 5

Hims & Hers Health and Novo Nordisk have resolved their legal dispute over compounded weight loss medications, announcing a surprise collaboration instead. This settlement marks a significant shift in the GLP-1 market, moving from aggressive litigation to a strategic alliance between a telehealth leader and a pharmaceutical giant.
Full story: https://gethealthbrief.com/story/hims-hers-novo-nordisk-settlement-collaboration

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.